Abstract:Regenerative medicine shows significant potential in treating kidney diseases through the application of various types of stem and progenitor cells, including mesenchymal stem cells (MSCs), renal stem/progenitor cells, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). Stem cells possess the unique ability to repair injured organs and improve impaired functions, making them a key element in the research of therapies for kidney tissue repair and organ regeneration. In kidney transplantation, reperfusion injury can cause tissue destruction, leading to an initially low glomerular filtration rate and long-term impact on function by creating irreversible interstitial fibrosis. MSCs have proven useful in repairing early tissue injury in animal models of kidney, lung, heart, and intestine transplantation. The use of stem cell therapies in solid organ transplantation raises the question of whether autologous or allogeneic cells should be preferred. Adipose-derived stem cells (ASCs), characterized by the lack of HLA Class II molecules and low expression of HLA Class I and co-stimulatory signals, are considered immune-privileged. However, the actual risk of graft rejection associated with allogeneic ASCs remains unclear. It has been demonstrated that donor-derived ASCs can promote the development of Treg cells in vitro, and some degree of tolerance induction has been observed in vivo. Nevertheless, a study comparing the efficacy of autologous and allogeneic ASCs in a rat model with a total MHC mismatch for kidney transplantation showed that donor-derived administration of ASCs did not improve the grafts' survival and was associated with increased mortality through an immunologically mediated mechanism. Given the lack of data, autologous ASCs appear to be a safer option in this research context. The aim of this review was to examine the differences between autologous and allogeneic ASCs in the context of their application in kidney transplantation therapies, considering potential immune reactions and therapeutic efficacy. Some have argued that ASCs harvested from end-stage renal disease (ESRD) patients may have lower regenerative potential due to the toxic effects of uremia, potentially limiting their use in transplantation settings. However, evidence suggests that the beneficial properties of ASCs are not affected by uremia or dialysis. Indeed, some investigators have demonstrated that ASCs harvested from chronic kidney disease (CKD) patients exhibit normal characteristics and function, maintaining consistent proliferative capacity and genetic stability over time, even after prolonged exposure to uremic serum Furthermore, no differences were observed in the response of ASCs to immune activation or their inhibitory effect on the proliferation of alloantigen-activated peripheral blood mononuclear cells between patients with normal or impaired renal function. This review presents the current achievements in stem cell research aimed at treating kidney diseases, highlighting significant progress and ongoing efforts in the development of stem cell-based therapies. Despite the encouraging results, further research is needed to overcome the current limitations and fully realize the potential of these innovative treatments. Advances in this field are crucial for developing effective therapies that can address the complex challenges associated with kidney damage and failure.

How Stem and Progenitor Cells Can Affect Renal Diseases

Stem cells in kidney diseases

Regenerative Medicine for the Kidney: Renotropic Factors, Renal Stem/Progenitor Cells, and Stem Cell Therapy

Mesenchymal Stem Cells-Potential Applications in Kidney Diseases

Immunological Considerations and Therapeutic Efficacy

Regenerative Abilities of Mesenchymal Stem Cells Via Acting As an Ideal Vehicle for Subcellular Component Delivery in Acute Kidney Injury

Cellular Senescence, A Novel Therapeutic Target For Mesenchymal Stem Cells In Acute Kidney Injury

Proliferative Capacity of Stem/progenitor-Like Cells in the Kidney May Associate with the Outcome of Patients with Acute Tubular Necrosis.

Progress in non-renal derived adult stem cell therapy for kidney disease

Genetic Communication by Extracellular Vesicles is an Important Mechanism Underlying Stem Cell-Based Therapy-Mediated Protection Against Acute Kidney Injury

Current Understanding of the Administration of Mesenchymal Stem Cells in Acute Kidney Injury to Chronic Kidney Disease Transition: a Review with a Focus on Preclinical Models

Frontiers in nephrology: the evolving therapeutic applications of endothelial progenitor cells

The Renoprotective and Anti-Inflammatory Effects of Human Urine-Derived Stem Cells on Acute Kidney Injury Animals

Impaired systemic proteostasis and peripheral immune cell dysfunction in kidney diseases

Progenitor-like cells derived from mouse kidney protect against renal fibrosis in a remnant kidney model via decreased endothelial mesenchymal transition

Kidney development at a glance: metabolic regulation of renal progenitor cells

Composite materials combined with stem cells promote kidney repair and regeneration

Regulated cell death pathways in kidney disease

Different Impacts of Subtotal Nephrectomy and Ischemia-Reperfusion Injury on Renal Stem Cells and Progenitor Cells of Rats and Their Significance for Renal Prognosis

Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases

The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis